Skip to content
Inciteful Med
Resources About us Ask a Question

What Are the Best Pain Management Strategies for hEDS?

Published: | Updated:

The best way to manage chronic pain in hypermobile Ehlers-Danlos Syndrome (hEDS) is a combined approach. This includes hypermobility-aware physical therapy to stabilize joints, physical supports like splints, and nerve-calming medications like Low-Dose Naltrexone instead of opioids or daily NSAIDs.

Key Takeaways

  • • Effective hEDS pain management requires a multimodal approach combining physical therapy, structural supports, and targeted medication.
  • • Hypermobility-aware physical therapy focuses on joint stabilization and strength rather than traditional stretching.
  • • Medications that calm the nervous system, like Low-Dose Naltrexone (LDN), are often preferred over opioids or oral NSAIDs.
  • • Physical supports like silver ring splints, braces, and compression garments help prevent painful joint subluxations.
  • • Learning nervous system regulation and pacing techniques is critical for managing the stress of unpredictable chronic pain flares.

The safest and most effective way to manage chronic pain in hypermobile Ehlers-Danlos Syndrome (hEDS) is through a personalized, multimodal approach—combining hypermobility-aware physical therapy, physical supports, specialized medications, and nervous system regulation [1][2][3]. Chronic pain in hEDS is severe, persistent, and a primary driver of disability [4][5]. Because hEDS pain is complex, often involving joint instability, nerve compression, and changes in how the brain processes pain signals, building a diverse toolkit is essential for long-term relief [6][5][7].

Understanding Your Pain

Pain in hEDS typically falls into two categories, both of which require different management strategies:

  • Mechanical and Nociceptive Pain: This is the structural pain caused by frequent subluxations (partial joint dislocations), muscle spasms, and tissue damage from joint instability [4].
  • Neuropathic and Centralized Pain: Many people with hEDS develop neuropathic pain (nerve pain) from irritated, stretched, or pinched nerves [7]. A related issue is small fiber neuropathy, which damages the tiny nerve endings in the skin and causes burning or tingling sensations [8]. Additionally, the constant barrage of pain signals from the body can lead to central sensitization—a condition where the central nervous system becomes highly reactive, amplifying pain and causing non-painful stimuli to hurt [9][10].

Hypermobility-Aware Physical Therapy

While standard physical therapy often focuses on stretching to regain range of motion, this can be harmful for hEDS patients whose joints are already too loose [11]. Instead, specialized physical therapy is the foundational treatment for mechanical pain [11][12].

  • Targeted Strengthening: Therapy focuses on building muscle strength to compensate for faulty, lax ligaments [13][12].
  • Proprioception Training: Exercises that help your brain better understand where your body is in space (proprioception) can reduce the frequency of subluxations [14][15].

Physical Supports and Acute Flare Tools

Protecting unstable joints reduces daily strain, while at-home tools can help manage acute flares when a joint slips out of place:

  • Orthoses and Splints: Devices like silver ring splints for fingers can prevent joints from bending backward (hyperextending), reducing pain and improving your ability to use your hands [16][17]. Larger braces may be used for other unstable joints to provide support [11].
  • Compression Garments: Tight clothing and specialized dynamic elastomeric fabric orthoses can improve joint awareness and have been shown to reduce pain and the need for painkillers [18][19].
  • At-Home Modalities: TENS units (devices that send mild electrical pulses to the skin), heating pads, and cold therapy are accessible, non-pharmacological tools frequently used to manage localized pain and acute muscle spasms safely [20][1].

Pharmacological Options (Medications)

Medication strategies for hEDS often borrow from treatments for fibromyalgia and nerve pain, focusing on calming an overactive nervous system rather than just numbing the joints [5][6].

First-Line and Daily Medications

  • Topical Treatments: Because of systemic issues, topical NSAIDs (like diclofenac gel) or lidocaine patches are often preferred for localized joint pain, as they bypass the digestive tract [20][21].
  • Low-Dose Naltrexone (LDN): Naltrexone acts as a pain modulator and anti-inflammatory at very low doses, calming the immune cells in the nervous system [22][23]. It is frequently prescribed off-label for hEDS because it generally has a favorable safety profile and minimal side effects compared to traditional painkillers [24][25].
  • SNRIs and Gabapentinoids: Medications that target the nervous system—such as SNRIs (e.g., Duloxetine) and gabapentinoids (e.g., Gabapentin)—are frequently utilized to treat central sensitization and nerve pain [9][10].
  • Note: Centralized pain medications, including LDN, often take weeks to reach full efficacy and are not instant rescue drugs [20].

Medications to Limit or Approach with Caution

  • Oral NSAIDs (Ibuprofen, Naproxen): People with hEDS have a high prevalence of gastrointestinal (GI) issues and comorbidities like Mast Cell Activation Syndrome (MCAS) [26][27]. Chronic, daily use of oral NSAIDs dramatically increases the risk of serious GI injury and bleeding in this population [21][28].
  • Opioids: Long-term opioid use is generally discouraged. Comorbidities like Postural Orthostatic Tachycardia Syndrome (POTS) already slow down digestion; opioids can severely worsen this, causing dangerous and painful constipation [21][29]. Additionally, opioids can trigger hyperalgesia (increased pain sensitivity) over time, which actively worsens central sensitization [28][4].

Nervous System Regulation and Coping Strategies

Living with a fragile body and unpredictable pain takes a massive toll, often compounded by medical trauma or having symptoms dismissed. Tools to manage this burden are not suggested because the pain is “in your head,” but because the brain is the control center for pain processing, and chronic pain is inherently stressful [1][30].

  • Coping and Regulation: Interventions that focus on nervous system regulation and building coping strategies for unpredictable pain flares are essential for improving quality of life and navigating medical trauma [1][30].
  • Pacing and Specialized Programs: Online programs like HOPE (Hypermobile Online Pain managemEnt) have been specifically developed with patient input to help those with hEDS learn to self-manage pain through energy conservation and emotional support [31][32]. Pacing is critical, as balancing your daily activities directly impacts your post-activity pain and fatigue [33].

Frequently Asked Questions

What kind of physical therapy is best for hEDS?
Hypermobility-aware physical therapy focuses on targeted muscle strengthening and spatial awareness rather than traditional stretching. This approach helps stabilize loose joints and reduces the frequency of painful subluxations.
Why are oral NSAIDs and opioids often avoided for hEDS pain?
Many people with hEDS have gastrointestinal issues and autonomic conditions like POTS. Daily oral NSAIDs increase the risk of stomach bleeding, while opioids can cause severe constipation and even increase pain sensitivity over time.
Does Low-Dose Naltrexone (LDN) help with hEDS pain?
Yes, Low-Dose Naltrexone is frequently prescribed off-label for hEDS because it acts as a pain modulator and reduces inflammation in the nervous system. It has a favorable safety profile but can take weeks to reach full effectiveness.
Why does hEDS cause burning or tingling nerve pain?
Nerve pain in hEDS often comes from nerves being stretched or pinched by unstable joints. Some patients also develop small fiber neuropathy or central sensitization, where the nervous system becomes highly reactive to everyday signals.
How can I manage acute hEDS joint pain flares at home?
At-home tools like TENS units, heating pads, and cold therapy can safely manage localized pain and muscle spasms. Additionally, braces, compression garments, and silver ring splints help protect unstable joints from slipping out of place.

Questions for Your Doctor

  • • What is my specific mix of mechanical versus nerve pain, and how should we tailor my medications to address this?
  • • Are you comfortable prescribing and monitoring off-label treatments like Low-Dose Naltrexone (LDN) for central sensitization?
  • • Can you refer me to a physical therapist who specifically understands hypermobility and joint stabilization, rather than traditional stretching?
  • • Given my GI and autonomic symptoms, how can we safely manage acute pain flares without relying on oral NSAIDs or opioids?
  • • Which specific joints would benefit most from stabilization with braces, ring splints, or compression garments?

Questions for You

  • • Do I notice my pain feeling more like a dull, deep ache (mechanical/structural) or a burning, stinging sensation (nerve)?
  • • Which of my joints feel the most unstable during the day, and do I have any physical supports to help them?
  • • How do my current pain medications affect my digestion, and are they causing more side effects than benefits?
  • • What activities consistently trigger severe pain flares, and how can I pace myself better to conserve energy?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Fear avoidance, fear of falling, and pain disability in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.

    Chuchin JD, Ornstein TJ

    Disability and rehabilitation 2024; (46(18)):4234-4245 doi:10.1080/09638288.2023.2268520.

    PMID: 37843031
  2. 2

    Integrative medicine for hypermobility spectrum disorders (HSD) and Ehlers-Danlos syndromes (EDS): a feasibility study.

    Guedry SE, Langley BO, Schaefer K, Hanes DA

    Disability and rehabilitation 2024; (46(24)):5854-5867 doi:10.1080/09638288.2024.2314713.

    PMID: 38353245
  3. 3

    The Spider: a visual, multisystemic symptom impact questionnaire for people with hypermobility-related disorders-validation in adults.

    Ewer ER, De Pauw R, Kazkazk H, et al.

    Clinical rheumatology 2024; (43(9)):3005-3017 doi:10.1007/s10067-024-07071-7.

    PMID: 39085705
  4. 4

    Evidence for central sensitization as classified by the central sensitization inventory in patients with pain and hypermobility.

    Desai MJ, Brestle M, Jonely H

    Pain practice : the official journal of World Institute of Pain 2025; (25(1)):e13411 doi:10.1111/papr.13411.

    PMID: 39192465
  5. 5

    Pain in hypermobile Ehlers-Danlos syndrome: New insights using new criteria.

    Bénistan K, Martinez V

    American journal of medical genetics. Part A 2019; (179(7)):1226-1234 doi:10.1002/ajmg.a.61175.

    PMID: 31075184
  6. 6

    Central sensitization as the mechanism underlying pain in joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type.

    Di Stefano G, Celletti C, Baron R, et al.

    European journal of pain (London, England) 2016; (20(8)):1319-25 doi:10.1002/ejp.856.

    PMID: 26919608
  7. 7

    Hypothesis paper: high prevalence of Tinel sign in hypermobile Ehlers-Danlos syndrome.

    Hashemi SS, Knight DRT

    Frontiers in neurology 2025; (16()):1508176 doi:10.3389/fneur.2025.1508176.

    PMID: 41245868
  8. 8

    Hypermobile Ehlers-Danlos Syndrome: Cerebrovascular, Autonomic and Neuropathic Features.

    Novak P, Systrom DM, Marciano SP, et al.

    American journal of medicine open 2025; (14()):100111 doi:10.1016/j.ajmo.2025.100111.

    PMID: 40843452
  9. 9

    Pain due to Ehlers-Danlos Syndrome Is Associated with Deficit of the Endogenous Pain Inhibitory Control.

    Leone CM, Celletti C, Gaudiano G, et al.

    Pain medicine (Malden, Mass.) 2020; (21(9)):1929-1935 doi:10.1093/pm/pnaa038.

    PMID: 32176287
  10. 10

    Exploring signs of central sensitization in adolescents with hypermobility Spectrum disorder or hypermobile Ehlers-Danlos syndrome.

    Schubert-Hjalmarsson E, Fasth A, Ickmans K, et al.

    European journal of pain (London, England) 2025; (29(1)):e4754 doi:10.1002/ejp.4754.

    PMID: 39529262
  11. 11

    Physical and mechanical therapies for lower limb symptoms in children with Hypermobility Spectrum Disorder and Hypermobile Ehlers-Danlos Syndrome: a systematic review.

    Peterson B, Coda A, Pacey V, Hawke F

    Journal of foot and ankle research 2018; (11()):59 doi:10.1186/s13047-018-0302-1.

    PMID: 30455744
  12. 12

    Home-based exercise therapy for treating shoulder instability in patients with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders. A randomized trial.

    Spanhove V, De Wandele I, Malfait F, et al.

    Disability and rehabilitation 2023; (45(11)):1811-1821 doi:10.1080/09638288.2022.2076932.

    PMID: 35609204
  13. 13

    A randomised controlled trial of heavy shoulder strengthening exercise in patients with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome and long-lasting shoulder complaints: study protocol for the Shoulder-MOBILEX study.

    Liaghat B, Skou ST, Søndergaard J, et al.

    Trials 2020; (21(1)):992 doi:10.1186/s13063-020-04892-0.

    PMID: 33261635
  14. 14

    Ehlers-Danlos Syndrome, Hypermobility Type: Impact of Somatosensory Orthoses on Postural Control (A Pilot Study).

    Dupuy EG, Leconte P, Vlamynck E, et al.

    Frontiers in human neuroscience 2017; (11()):283 doi:10.3389/fnhum.2017.00283.

    PMID: 28642694
  15. 15

    Pain Management through Neurocognitive Therapeutic Exercises in Hypermobile Ehlers-Danlos Syndrome Patients with Chronic Low Back Pain.

    Celletti C, Paolucci T, Maggi L, et al.

    BioMed research international 2021; (2021()):6664864 doi:10.1155/2021/6664864.

    PMID: 34124258
  16. 16

    Finger orthoses for management of joint hypermobility disorders: Relative effects on hand function and cognitive load.

    Jensen AM, Andersen JQ, Quisth L, Ramstrand N

    Prosthetics and orthotics international 2021; (45(1)):36-45 doi:10.1177/0309364620956866.

    PMID: 33834743
  17. 17

    PATIENT-REPORTED OUTCOMES FOR USE OF SILVERSPLINTS IN OSTEOARTHRITIS OF THE HAND.

    Roux N, VAN DER Windt JW, Akkerman W, Toor M

    Journal of rehabilitation medicine. Clinical communications 2021; (4()):1000060 doi:10.2340/20030711-1000060.

    PMID: 34276904
  18. 18

    The value of dynamic elastomeric fabric orthoses in the management of a complex hypermobile Ehlers-Danlos syndrome patient: A case report.

    Higo A, Pearce G, Palmer S, Grant L

    Clinical case reports 2023; (11(1)):e6821 doi:10.1002/ccr3.6821.

    PMID: 36694653
  19. 19

    Compression garments in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: a retrospective cohort study.

    Boulu X, Karam JD, Schmidt J

    BMC musculoskeletal disorders 2025; (26(1)):1066 doi:10.1186/s12891-025-09318-z.

    PMID: 41286814
  20. 20

    Management of childbearing with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: A scoping review and expert co-creation of evidence-based clinical guidelines.

    Pezaro S, Brock I, Buckley M, et al.

    PloS one 2024; (19(5)):e0302401 doi:10.1371/journal.pone.0302401.

    PMID: 38748660
  21. 21

    The prevalence of multisystem diagnoses among young patients with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder: A retrospective analysis using a large healthcare claims database.

    Kozyra M, Kostyun R, Strecker S

    Medicine 2024; (103(41)):e39212 doi:10.1097/MD.0000000000039212.

    PMID: 39465806
  22. 22

    Successful treatment of dermatomyositis with low-dose naltrexone.

    Tran T, Chen A, Worswick S

    Dermatologic therapy 2018; (31(6)):e12720 doi:10.1111/dth.12720.

    PMID: 30246915
  23. 23

    Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review.

    Hatfield E, Phillips K, Swidan S, Ashman L

    Journal of the American Dental Association (1939) 2020; (151(12)):891-902.e1 doi:10.1016/j.adaj.2020.08.019.

    PMID: 33228882
  24. 24

    Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis.

    Driver CN, D'Souza RS

    Biomedicines 2023; (11(4)) doi:10.3390/biomedicines11041087.

    PMID: 37189705
  25. 25

    The Use of Low-Dose Naltrexone for Chronic Pain.

    Bostick KM, McCarter AG, Nykamp D

    The Senior care pharmacist 2019; (34(1)):43-46 doi:10.4140/TCP.n.2019.43.

    PMID: 30821677
  26. 26

    The association between Ehlers-Danlos syndrome-hypermobility type and gastrointestinal symptoms in university students: a cross-sectional study.

    Fikree A, Aktar R, Morris JK, et al.

    Neurogastroenterology and motility 2017; (29(3)) doi:10.1111/nmo.12942.

    PMID: 27683076
  27. 27

    Gastrointestinal Symptoms in Marfan Syndrome and Hypermobile Ehlers-Danlos Syndrome.

    Inayet N, Hayat JO, Kaul A, et al.

    Gastroenterology research and practice 2018; (2018()):4854701 doi:10.1155/2018/4854701.

    PMID: 30151001
  28. 28

    An overview of Ehlers Danlos syndrome and the link between postural orthostatic tachycardia syndrome and gastrointestinal symptoms with a focus on gastroparesis.

    Wu W, Ho V

    Frontiers in neurology 2024; (15()):1379646 doi:10.3389/fneur.2024.1379646.

    PMID: 39268060
  29. 29

    Analysis of Antroduodenal Motility in Patients With Hypermobility Spectrum Disorders/Hypermobile Ehlers-Danlos Syndrome.

    Sweerts KWE, Mujagic Z, Keszthelyi D, Conchillo JM

    Alimentary pharmacology & therapeutics 2025; (61(4)):702-705 doi:10.1111/apt.18471.

    PMID: 39745483
  30. 30

    Depressive symptoms are highly prevalent and associated with fatigue and pain catastrophizing in the Hypermobility Spectrum Disorders and hypermobile Ehlers Danlos syndrome: a cross-sectional study.

    Fletcher EKS, Fischer AL, Manocha RHK

    Rheumatology international 2025; (45(5)):128 doi:10.1007/s00296-025-05869-5.

    PMID: 40293579
  31. 31

    HOPE for Hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorder (HSD)-A Pilot Randomised Controlled Trial of Feasibility, Acceptability and Appropriateness.

    Chew MT, Ilhan E, Nicholson LL, et al.

    European journal of pain (London, England) 2025; (29(6)):e70030 doi:10.1002/ejp.70030.

    PMID: 40298033
  32. 32

    An online pain management program for people with hypermobile Ehlers-Danlos Syndrome or hypermobility spectrum disorder: a three-staged development process.

    Chew MT, Ilhan E, Nicholson LL, et al.

    Disability and rehabilitation 2025; (47(2)):414-424 doi:10.1080/09638288.2024.2351180.

    PMID: 38738812
  33. 33

    Perceived quality of life, fatigue and the metabolic cost of walking in generalized hypermobility spectrum disorder and hypermobile Ehlers-Danlos syndrome.

    Ladell AJM, Golden DW, Oliemans JP, et al.

    Frontiers in rehabilitation sciences 2025; (6()):1706912 doi:10.3389/fresc.2025.1706912.

    PMID: 41394316

This page discusses pain management strategies for hEDS for informational purposes only. Always consult your rheumatologist or pain management specialist before starting new medications or altering your physical therapy routine.

Stay up to date

Get notified when new research about Hypermobile Ehlers-Danlos Syndrome (hEDS) is published.

No spam. Unsubscribe anytime.